Sanofi develops Principa’s drug for multiple sclerosis
Sanofi will develop Principia Biopharma`s experimental oral treatment that could tackle multiple sclerosis (MS) and, maybe other central nervous system…
Pharmaceuticals, Biotechnology and Life Sciences
Sanofi will develop Principia Biopharma`s experimental oral treatment that could tackle multiple sclerosis (MS) and, maybe other central nervous system…
Bavarian Nordic has started the Phase 2 extension study of MVA-BN RSV, a universal vaccine candidate designed to elicit a broad…
Novartis on Wednesday announced positive topline results from the global MONALEESA-7 trial, the second Phase III trial of Kisqali in…
Diplomat Pharmacy, has entered into a definitive agreement to acquire Pharmaceutical Technologies, doing business as National Pharmaceutical Services. The transaction…
Novartis on Monday said that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for…
TiGenix NV has converted €7 million of its senior unsecured convertible bonds due 2018. The company said that, through this…
Boehringer Ingelheim and Dicerna Pharmaceuticals have announced a research collaboration and license agreement to discover and develop novel GalXC RNAi…
GlaxoSmithKline said on Thursday that its investigational BCMA antibody-drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration…
Sanofi’s Q3 2017 sales performance were supported by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets, and it saw net sales…